A Sequential Cohort Study Exploring GELCLAIR in the Management of Oral Mucositis in Patients Receiving Radical Radiation for Head and Neck Cancer

Launched by NOVA SCOTIA HEALTH AUTHORITY · Mar 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether Gelclair, a lubricant gel, can help manage a painful condition called Oral Mucositis (OM) in patients with head and neck cancer who are receiving radiation therapy. The main focus is to find out if Gelclair can reduce the symptoms and severity of OM, which can make it difficult to swallow and cause significant pain. Participants in the trial will either use Gelclair or a standard mouthwash treatment for OM, and they will report their symptoms and any side effects weekly for up to four weeks after finishing their radiation treatment.

To be eligible for the trial, participants need to be diagnosed with a specific type of throat or mouth cancer and be receiving a certain amount of radiation therapy. They should also be likely to develop OM based on their treatment. The trial is open to both men and women, and participants will need to be able to read and understand English. Since the trial is not yet recruiting, there will be more information available soon for those who are interested in participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with primary mucosal squamous cell carcinoma of the oropharynx or oral cavity
• • Treatment plan includes at least 60Gy of daily radiotherapy, with or without concurrent chemotherapy
• • Highly likely to develop OM CTCAE v5.0, grade 2
• • Can read and understand English
• Exclusion Criteria:
• • - Patients who already have parenteral feeding tubes prescribed